Estimating the Gender Distribution of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis

Abstract

Introduction This study investigates the gender distribution in patients diagnosed with wild-type transthyretin amyloidosis cardiomyopathy (ATTRwt). Methods A systematic review and meta-analysis of the male proportion in diagnosed ATTRwt patients were conducted. To avoid overlapping population, pooled estimates in the primary analysis were based on all unique studies. In secondary analyses, we considered predefined subsets of studies based on study sample size, recruitment years, geography, study design, age at diagnosis, and method of diagnosis. Additional meta-regression analyses were tested for potential determinants of gender distribution. Results Twenty-eight unique studies (2542 patients) were included in the meta-analysis. Male proportion in patients with ATTRwt was 86.9% (95% confidence interval 81.5–91.6%). Studies, including patients older than 80 years at diagnosis, had a 29.1% ( p value < 0.001) lower male proportion compared to studies, including younger patients. After adjusting for age, studies using autopsy as a method of diagnosis had a 21.1% ( p value 0.002) lower male proportion compared to other studies. Conclusions Studies conducted to date suggest ATTRwt disproportionally affects males. The proportion of males was significantly impacted by the age at diagnosis and method diagnosis, which may suggest important gender-based differences in the clinical manifestation and diagnostic challenges of ATTRwt in females that warrant future research. Electronic supplementary material The online version of this article (10.1007/s40119-020-00205-3) contains supplementary material, which is available to authorized users.

Baseline Characteristics and Secondary Medication Adherence Patterns Among Patients Receiving Tafamidis Prescriptions: A Retrospective Analysis Using a National Specialty Pharmacy Dispensing Database

“…In this analysis 83% of the patients were male, a proportion that is less skewed than published reports with male to female ratio estimates ranging from 10:1 to 20:1, 33–38 but in-line with the level of male predominance reported in two recent systematic literature (83% and 86%). 39 , 40 Among healthcare practitioners whose specialty was specified, cardiologists were the primary prescribers of tafamidis.…”

Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy

“…This leads to restrictive cardiomyopathy, progressive heart failure and increased risk of conduction abnormalities and arrhythmias [1]. The more common wild-type form (ATTRwt-CM) is associated with aging, with symptom onset typically occurring at age 60 years or older, and is diagnosed predominantly in males [3][4][5]. The prevalence of ATTRwt-CM is not well characterized, but the condition is thought to be under recognized [1,2].…”

Trends in the amyloidosis mortality rate in Japan: A nationwide observational study from 1998 to 2019

“…Of note, age‐adjusted mortality in men has increased 1.54‐fold over the past 6 years, with a marked increasing trend. Among AL and ATTRwt amyloidosis, which causes fatal cardiac amyloidosis, 55% of AL and 87% of ATTRwt amyloidosis cases are reported to be diagnosed in men 23,24 . Although the statistics used in this study do not include the breakdown of AL and ATTRwt amyloidosis, it is possible that the marked increase in ATTRwt cases affected the gender differences observed in this study.…”